237 related articles for article (PubMed ID: 19796580)
1. Liver X receptors as potential therapeutic targets in atherosclerosis.
Zhu Y; Li Y
Clin Invest Med; 2009 Oct; 32(5):E383-94. PubMed ID: 19796580
[TBL] [Abstract][Full Text] [Related]
2. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice.
Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG
J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817
[TBL] [Abstract][Full Text] [Related]
3. Liver X receptor: a potential target in the treatment of atherosclerosis.
Savla SR; Prabhavalkar KS; Bhatt LK
Expert Opin Ther Targets; 2022 Jul; 26(7):645-658. PubMed ID: 36003057
[TBL] [Abstract][Full Text] [Related]
4. Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).
Li X; Yeh V; Molteni V
Expert Opin Ther Pat; 2010 Apr; 20(4):535-62. PubMed ID: 20302451
[TBL] [Abstract][Full Text] [Related]
5. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
Ishibashi M; Filomenko R; Rébé C; Chevriaux A; Varin A; Derangère V; Bessède G; Gambert P; Lagrost L; Masson D
Biochem Pharmacol; 2013 Jul; 86(1):122-9. PubMed ID: 23313547
[TBL] [Abstract][Full Text] [Related]
6. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
Breevoort SR; Angdisen J; Schulman IG
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
[TBL] [Abstract][Full Text] [Related]
7. Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists.
Griffett K; Hayes M; Bedia-Diaz G; Appourchaux K; Sanders R; Boeckman MP; Koelblen T; Zhang J; Schulman IG; Elgendy B; Burris TP
ACS Chem Biol; 2022 May; 17(5):1143-1154. PubMed ID: 35417135
[TBL] [Abstract][Full Text] [Related]
8. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
Fiévet C; Staels B
Biochem Pharmacol; 2009 Apr; 77(8):1316-27. PubMed ID: 19101522
[TBL] [Abstract][Full Text] [Related]
9. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE.
Bradley MN; Hong C; Chen M; Joseph SB; Wilpitz DC; Wang X; Lusis AJ; Collins A; Hseuh WA; Collins JL; Tangirala RK; Tontonoz P
J Clin Invest; 2007 Aug; 117(8):2337-46. PubMed ID: 17657314
[TBL] [Abstract][Full Text] [Related]
10. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design.
Oosterveer MH; Grefhorst A; Groen AK; Kuipers F
Prog Lipid Res; 2010 Oct; 49(4):343-52. PubMed ID: 20363253
[TBL] [Abstract][Full Text] [Related]
11. Liver X receptor in cholesterol metabolism.
Zhao C; Dahlman-Wright K
J Endocrinol; 2010 Mar; 204(3):233-40. PubMed ID: 19837721
[TBL] [Abstract][Full Text] [Related]
12. LXR{beta} is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux.
Hessvik NP; Boekschoten MV; Baltzersen MA; Kersten S; Xu X; Andersén H; Rustan AC; Thoresen GH
Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E602-13. PubMed ID: 19996385
[TBL] [Abstract][Full Text] [Related]
13. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis.
Millatt LJ; Bocher V; Fruchart JC; Staels B
Biochim Biophys Acta; 2003 Mar; 1631(2):107-18. PubMed ID: 12633677
[TBL] [Abstract][Full Text] [Related]
14. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
[TBL] [Abstract][Full Text] [Related]
15. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis.
Lo Sasso G; Murzilli S; Salvatore L; D'Errico I; Petruzzelli M; Conca P; Jiang ZY; Calabresi L; Parini P; Moschetta A
Cell Metab; 2010 Aug; 12(2):187-93. PubMed ID: 20674863
[TBL] [Abstract][Full Text] [Related]
16. Liver x receptor signaling pathways and atherosclerosis.
Calkin AC; Tontonoz P
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1513-8. PubMed ID: 20631351
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates.
Kirchgessner TG; Martin R; Sleph P; Grimm D; Liu X; Lupisella J; Smalley J; Narayanan R; Xie Y; Ostrowski J; Cantor GH; Mohan R; Kick E
J Pharmacol Exp Ther; 2015 Feb; 352(2):305-14. PubMed ID: 25467132
[TBL] [Abstract][Full Text] [Related]
18. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
[TBL] [Abstract][Full Text] [Related]
19. Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists.
Nomura S; Endo-Umeda K; Makishima M; Hashimoto Y; Ishikawa M
ChemMedChem; 2016 Oct; 11(20):2347-2360. PubMed ID: 27690261
[TBL] [Abstract][Full Text] [Related]
20. Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.
Bischoff ED; Daige CL; Petrowski M; Dedman H; Pattison J; Juliano J; Li AC; Schulman IG
J Lipid Res; 2010 May; 51(5):900-6. PubMed ID: 20388921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
